Abstract:Importance: Aquaporin-4 (AQP4) plays a critical role in the glymphatic system, responsible for clearing brain solutes like Abeta peptides. Exploring AQP4 as an Alzheimer's disease (AD) biomarker might aid in the understanding of AD neuropathology and monitor the effects of novel drug candidates on the glymphatic system. Objective: To determine the potential of CSF AQP4 as an early stage AD biomarker using a newly established immunoassay. Design: A discovery cohort (n = 157) (2010-2022), composed by AD patients, other neurodegenerative conditions and controls (CON), was used to assess the diagnostic performance of CSF AQP4. Subsequently, AQP4 concentration across the clinical AD spectrum was analyzed in two independent validation cohorts (n = 176) (2016-2023). Stratified randomization based on diagnosis and blinded analyses were performed. Setting Multicenter study: Ulm University Hospital (discovery), University of Perugia (validation cohort I), University Hospital of Torino (validation cohort II). Participants: Discovery cohort: 38 CON, 40 AD, 21 primary progressive aphasia, 20 behavioural variant frontotemporal dementia, 17 amyotrophic lateral sclerosis (ALS), and 21 Lewy body disease (LBD). Validation cohorts: 55 CON, 14 preclinical AD, 51 AD with mild cognitive impairment (AD-MCI), 39 AD dementia (ADD) and 17 mild cognitive impairment with non-AD pathology (non-AD MCI). The discovery cohort was selected through random sampling, while validation cohort I and II followed a consecutive sampling method. Exposures: CSF AQP4 Main Outcome (s) and Measure (s): AQP4 CSF biomarker detection Results: A total of 333 participants were included in this study. In the discovery cohort, the median (IQR) age was 69 (61-75) years and 46.5% of the cohort were women. CSF AQP4 concentration was increased in AD patients compared to CON (p < 0.001), ALS (p = 0.015), and LBD (p = 0.012) patients. CSF AQP4 in AD patients were further analyzed in validation cohort I (median (IQR) age, 74 (71-77) years; 62.0% women), and II (median (IQR) age, 71 (65-75) years; 58.5% women). When analyzing the different stages of the AD continuum in validation cohort I, AD-MCI (p = 0.011) and ADD (p = 0.002) patients had significantly higher AQP4 concentrations than CON. Similar results were obtained in cohort II, where AQP4 levels were higher in AD-MCI (p < 0.001) and ADD (p = 0.028) patients compared to controls. The AQP4 accuracy (area under the receiver operating characteristic curve [AUC]) to distinguish AD patients from CON was 0.81 (95% CI: 0.71 to 0.90, p <0.001) in the discovery cohort, 0.70 (95% CI: 0.60 to 0.81, p<0.001) in validation cohort I and 0.82 (95% CI 0.71 to 0.94, p <0.001) in II. Moreover, patients with AD-MCI could be distinguished from non-AD MCI with an AUC of 0.79 (95% CI: 0.65 to 0.93, p = 0.002). Conclusions and Relevance: Three independent cohorts consistently showed elevated AQP4 levels in AD (including AD-MCI and ADD) compared to CON and other neurodegenerative conditions, suggesting specificity to AD pathology. These findings contribute to understanding AD neuropathology and propose AQP4 as a potential early biomarker of AD. Further investigations are needed to proof AQP4 as a fluid blood brain barrier damage marker.

Explainable artificial intelligence identifies an AQP4 polymorphism-based risk score associated with brain amyloid burden

Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden

Aquaporin-4 Polymorphisms Are Associated With Cognitive Performance in Parkinson’s Disease

Cerebrospinal fluid proteome profiling using machine learning shows a unique protein signature associated with APOE4 genotype

The Effects of AQP4 Rs162009 on Resting-State Brain Activity in Parkinson's Disease

Neuropathology‐based APOE genetic risk score better quantifies Alzheimer's risk

Aquaporin-4 as an early cerebrospinal fluid biomarker of Alzheimer's disease

Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype

Affect of APOE on Information Processing Speed in Non-Demented Elderly Population: a Preliminary Structural MRI Study

Data‐driven approach reveals heterogeneity and region‐specific association of white matter hyperintensities with the APOE genotype

Unbiased deep learning assessment of APOE4 risk for sporadic Alzheimer’s disease

Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits

Association of AQP4 single nucleotide polymorphisms (rs335929 and rs2075575) with Parkinson's disease: a case-control study

APOE genotype or presence of brain amyloid alters the plasma proteome in cognitively normal, elderly subjects

Glymphatic system, AQP4, and their implications in Alzheimer’s disease

Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults

APOE4 and Chronic Health Risk Factors are Associated with Sex-Specific Preclinical Alzheimers Disease Neuroimaging Biomarkers

Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE Ε 4 Non-Carriers of Alzheimer's Disease.

APOE Influences Working Memory in Non-Demented Elderly Through an Interaction with SPON1 Rs2618516

Investigating APOE, APP-Aβ metabolism genes and Alzheimer’s disease GWAS hits in brain small vessel ischemic disease

Integrated genomic analysis revealed associated genes for Alzheimer's disease in APOE4 non-carriers.